Phaseline

Companies › Zura Bio

Zura Bio: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 2 Phase 2; Immunology, Infectious disease; next expected readout Apr 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Tibulizumab (ZB-106)
Tumor necrosis factor ligand superfamily member 13B inhibitor; Interleukin 17A inhibitor
TNFSF13B, IL17APhase 2Hidradenitis Suppurativa (HS); Systemic Sclerosis (SSc)Apr 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06993610Tibulizumab (ZB-106)Phase 2Hidradenitis Suppurativa (HS)Infectious diseaseApr 2027
NCT06843239Tibulizumab (ZB-106)Phase 2Systemic Sclerosis (SSc)ImmunologyMay 2027

From the company's SEC filings

Cash of $188m on 2026-09-30; operating cash outflow about $0m a year; runway about 28288 months at that burn, to Mar 4381; 2 of 2 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Agreements filed with the SEC (item 1.01), last two years

Specialist investors

Held by 8 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

TNFSF13B (1) IL17A (1)

Companies with the same targets

Celltrion GSK Vera Therapeutics Luminary Therapeutics Novartis MoonLake Immunotherapeutics Suzhou Suncadia Biopharmaceuticals Biocad UCB Biopharma SRL Eli Lilly

Companies built like this

MoonLake Immunotherapeutics Q32 Bio AnaptysBio RAPT Therapeutics, Inc., a member of the GSK plc group of companies Trellis Bioscience

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.